Research Article
Formulation and Optimization of Eudragit RS PO-Tenofovir Nanocarriers Using Box-Behnken Experimental Design
Table 3
Observed responses in BBD for Eudragit RS PO nanoparticles.
| Formulation code | Variable levels in coded form | Dependent variables | | | | PS (nm ± SD) | PDI (±SD) | ZP (mv ± SD) | EE (%) |
| 1 | | | 0 | | | | 98 | 2 | | | 0 | | | | 99 | 3 | | | 0 | | | | 99 | 4 | | | 0 | | | | 99 | 5 | | 0 | | | | | 99 | 6 | | 0 | | | | | 99 | 7 | | 0 | | | | | 99 | 8 | | 0 | | | | | 99 | 9 | 0 | | | | | | 99 | 10 | 0 | | | | | | 99 | 11 | 0 | | | | | | 99 | 12 | 0 | | | | | | 99 | 13 | 0 | 0 | 0 | | | | 99 | 14 | 0 | 0 | 0 | | | | 99 | 15 | 0 | 0 | 0 | | | | 99 |
|
|